Here's our latest list of notable financings that went free-trading in the money over the past few days. Read on for all the details.
Note: PrivatePlacements.com has NOT received compensation from any of the companies listed below in connection with this message, nor is the writer an investor in any company listed.
1. EV Nickel Inc. (TSX-V: EVNI)
- Gross proceeds: $2.1 million
- Number of units: 35 million
- Unit type: Special units
- Price per unit: $0.06
- Closing date: Sept. 15, 2023
- Today's share price (Jan. 22): $0.32
- Deal appreciation: ~433%
- Warrants: Full
- Strike Price: $0.09
- Expiry date: 09/14/26
Company breakdown:
EV Nickel is a Canadian nickel exploration company focused on the Shaw Dome project south of Timmins, Ontario. A resource estimate pegs the project with 2.0M tonnes at 0.98% nickel for a total of 43.3 million pounds between measured, indicated, and inferred.
Shares of the company have been on the rise since October, without much news, and even as the price of nickel has fallen. The company is currently in the permitting stage, and says it plans to start producing nickel in three to four years.
2. Clearmind Medicine Inc. (CSE: CMND)
- Gross proceeds: US$2.25 million
- Number of units: 7.5 million
- Unit type: Special units
- Price per unit: US$0.30
- Closing date: Sept. 18, 2023
- Today's share price (Jan. 22): $1.37
- Deal appreciation: ~357%
- Warrants: Full
- Strike Price: US$0.30
- Expiry date: 09/18/28
Company breakdown:
Clearmind Medicine is a biotech company exploring psychedelic-based therapeutics to solve problems like alcohol use disorder and depression. Shares of the company have been on a decline since around March 2023.
The above financing was brokered solely by Aegis Capital, and was offered at an absolutely enormous discount to its then share price of US$5.31 per share, which accounts for much of its high performance today. It also performed a 30:1 share rollback in November.
The company recently met with the U.S. Food and Drug Administration to discuss the clinical trial of its proprietary CMND-100 compound for the treatment of alcohol use disorder, which it aims to resubmit.
